Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2026 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

Entrada Therapeutics announces positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study.
May 06, 2026 16:30 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

Entrada Therapeutics will announce topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026.
March 12, 2026 07:50 ET | Source: Muscular Dystrophy Association

The 2026 MDA Clinical & Scientific Conference Highlights Breakthroughs in Neuromuscular Research, Innovative Therapies, and Patient Care

Orlando, Florida, March 12, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) concluded its 2026 MDA Clinical & Scientific Conference yesterday, convening over 2,400 attendees...
January 27, 2026 09:00 ET | Source: Muscular Dystrophy Association

Organizations Join Forces to Map How Human Muscle Regenerates

New York, Jan. 27, 2026 (GLOBE NEWSWIRE) -- A pivotal scientific collaboration born out of the Muscular Dystrophy Association’s (MDA) Muscle Regeneration Summit is advancing a first-of-its-kind...
January 08, 2026 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Entrada Therapeutics reports progress across its portfolio of RNA-based programs for the potential treatment of neuromuscular and ocular diseases.
December 10, 2025 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Announces More Than $2.7 Million For Research Grants to Advance Breakthroughs Across Neuromuscular Diseases

New York, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced more than $2.7 million in new research grants to advance groundbreaking discoveries across...
November 20, 2025 09:00 ET | Source: Muscular Dystrophy Association

NFL Players Lace Up for Muscular Dystrophy Association’s Mission in 2025 ‘My Cause My Cleats’ Campaign for Giving Tuesday

New York, Nov. 20, 2025 (GLOBE NEWSWIRE) -- This NFL season, during games in Weeks 12 and 13, hundreds of NFL players will step onto the field in custom-designed cleats as part of the 10th annual My...
October 15, 2025 09:00 ET | Source: Muscular Dystrophy Association

Agenda Announced for 2026 MDA Clinical & Scientific Conference Featuring Leading Speakers Dedicated to Groundbreaking Research and Clinical Achievements in Neuromuscular Disease

New York, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the agenda including tracks and chairs for the 2026 MDA Clinical & Scientific Conference...
September 05, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Entrada Therapeutics announces the recipients of its third annual DREAMS Grant Program.
August 23, 2025 16:42 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association and Parent Project Muscular Dystrophy Announce Joint Consensus Guidelines for Safe and Equitable Delivery of Gene Therapy in Duchenne Muscular Dystrophy

New York, Aug. 23, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and Parent Project Muscular Dystrophy (PPMD) today announced the publication of jointly developed consensus...